Arsanis (ASNS) IPO Opens Up 30%

Today's IPO for Arsanis, Inc. (NASDAQ: ASNS) opened for trading at $13 after pricing 4,000,000 shares of its common stock at a public offering price of $10.00 per share.

In addition, Arsanis has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of common stock from Arsanis at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.

In addition, a fund affiliated with New Enterprise Associates has agreed to purchase $20.0 million of Arsanis' common stock in a separate private placement concurrent with the completion of Arsanis' initial public offering at a price per share equal to the initial public offering price. The closing of the initial public offering is not conditioned upon the closing of the concurrent private placement.

Citigroup, Cowen and Company and Piper Jaffray & Co. are acting as joint book-running managers for the public offering and as placement agents for the concurrent private placement.

Arsanis, Inc. is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build and advance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets. The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureusinfections and is being evaluated in a Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.

Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).

You May Also Be Interested In

• SpaceX loses over $1 trillion in value from peak
• ISS backs Radoff-JEC nominees in Seer board dispute
• Csquare Opens At $20.90, IPO Priced at At $21